Part Two: How Innovation Can Broaden Access and Propel the CGT Industry Forward

In Part One of this two-part series, we reflected on the progress made in the Cell and Gene Therapy (CGT) industry and the importance of patient-centric development. In this episode, we dive into how we can continue to move forward, broaden access, and encourage the development of new treatments. We’ll discuss the critical need to scale manufacturing, even in the early stages of development, to ensure that these therapies reach the patients who need them.

Guests:

• Emma Chan, Director of Technical Development at Orchard Therapeutics
• Matt Hewitt, Chief Technical Officer at the Manufacturing Business Division at Charles River Laboratories